Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine

Bibliography

• Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population–a prevalence study. J Clin Epidemiol 1991;44(11):1147-57
   PubMed Web of Science ®Google Scholar
• Stewart WF, Shechter A, Lipton RB. Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Am Acad Neurol 1994;44(6 Suppl 4):S24-39
   Web of Science ®Google Scholar
• Lipton R, Bigal M, Kolodner K, Stewart W. The family impact of migraine: population based studies in the USA and UK. Cephalalgia 2003;23(6):429-40
   PubMed Web of Science ®Google Scholar
• Andlin-Sobocki P, Jönsson B, Wittchen H-U, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol 2005;12(Suppl):1-27
   PubMed Web of Science ®Google Scholar
• Hu XH, Markson LE, Lipton RB, Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999;159(8):813-18
   PubMed Web of Science ®Google Scholar
• Linde M, Gustavsson A, Stovner LJ, The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 2012;19(5):703-11
   PubMed Web of Science ®Google Scholar
• Lyngberg AC, Rasmussen BK, Jørgensen T, Jensen R. Secular changes in health care utilization and work absence for migraine and tension-type headache: a population based study. Eur J Epidemiol 2005;20(12):1007-14
   PubMed Web of Science ®Google Scholar
• Humphrey PPA. The discovery and development of the triptans, a major therapeutic breakthrough. Headache 2008;May48(5):685-7
   PubMed Web of Science ®Google Scholar
• Lipton R, Stewart W. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999;39(Suppl s2):20-6
   Google Scholar
• Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 2002;42(Suppl 1):3-9
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000;60(6):1259-87
   PubMed Web of Science ®Google Scholar
• Saxena PR, Tfelt-Hansen P. Triptans, 5HT1B/1D agonists in the acute treatment ofbmigraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, KMA W, editors. The headaches. 3rd edition. Lippincott Williams & Wilkins; Philadelphia: 2006. p. 469-503
   Google Scholar
• Visser WH, de Vriend RH, Jaspers MW, Ferrari MD. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Am Acad Neurol 1996;47(1):46-51
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. What can be learned from the history of recurrence in migraine? A comment. J Headache Pain 2009;10(5):311-15
   PubMed Web of Science ®Google Scholar
• Dilone E, Bergstrom D, Cabana B, Sumatriptan Lingual Spray Study Group. Rapid oral transmucosal absorption of sumatriptan, and pharmacodynamics in acute migraine. Headache 2009;49(10):1445-53
   PubMed Web of Science ®Google Scholar
• Pierce M, Marbury T, O'Neill C, Zelrix: a novel transdermal formulation of sumatriptan. Headache 2009;49(6):817-25
   PubMed Web of Science ®Google Scholar
• Brandes JL, Cady RK, Freitag FG, Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache 2009;49(10):1435-44
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment. J Headache Pain 2007;8(5):273-6
   PubMedGoogle Scholar
• Cady R, Wendt J, Kirchner J. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265:2831-5
   PubMed Web of Science ®Google Scholar
• Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325(5):316-21
   PubMed Web of Science ®Google Scholar
• Lance J. Sumatriptan-an oral dose-defining study. Eur Neurol 1991;31(5):300-5
   PubMed Web of Science ®Google Scholar
• Maassen van den Brink A, Reekers M, Bax WA, Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998;98(1):25-30
   PubMed Web of Science ®Google Scholar
• Olesen J, Burstein R, Ashina M, Tfelt-Hansen P. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol 2009;8(7):679-90
   PubMed Web of Science ®Google Scholar
• Monteith TS, Goadsby PJ. Acute migraine therapy: new drugs and new approaches. Curr Treat Options Neurol 2011;13(1):1-14
   PubMed Web of Science ®Google Scholar
• Asghar MS, Hansen AE, Amin FM, Evidence for a vascular factor in migraine. Ann Neurol 2011;69(4):635-45
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358(9294):1668-75
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Schwedt T. Cluster headache–acute and prophylactic therapy. Headache 2011;51(2):272-86
   PubMed Web of Science ®Google Scholar
• Brennum J, Brinck T, Schriver L. Sumatriptan has no clinically relevant effect in the treatment of episodic tension‐type headache. Eur J Neurol 1996;3(1):23-8
   Web of Science ®Google Scholar
• Tfelt-Hansen P. Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials. Cephalalgia 1993;13(4):238-44
   PubMed Web of Science ®Google Scholar
• Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998;38(3):184-90
   PubMed Web of Science ®Google Scholar
• Rapoport AM, Freitag F, Pearlman SH. Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs 2010;24(11):929-40
   PubMed Web of Science ®Google Scholar
• Schulman EA. Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea. Headache 2012;52(2):204-12
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. Low efficacy of transdermal sumatriptan in migraine. CNS Drugs 2011;25:2):171; authorreply171–3
   Web of Science ®Google Scholar
• Freitag FG. Sumatriptan needle-free subcutaneous (Sumavel(®) DosePro™) approved for the acute treatment of migraine, with or without aura, and cluster headaches. Expert Rev Neurother 2011;11(4):481-90
   PubMed Web of Science ®Google Scholar
• Cady RK, Aurora SK, Brandes JL, Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptans. Headache 2011;51(8):1202-11
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Olesen J. Increasing the effect of triptans in migraine. Lancet 2006;368(9544):1313-14
   PubMed Web of Science ®Google Scholar
• Winner P, Landy S, Richardson M, Ames M. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. Clin Ther 2005;27(11):1785-94
   PubMed Web of Science ®Google Scholar
• Smith TR, Sunshine A, Stark SR, Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 2005;45(8):983-91
   PubMed Web of Science ®Google Scholar
• Brandes JL, Kudrow D, Stark SR, Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA 2007;297(13):1443-54
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Rolan P. Nonsteriodal anti-inflammatory drugs in the acute treatment of migraine. In: Olesen J, Goadsby P, Ramadan N, Tfelt-Hansen P, Welch K, editors. The headaches. 3rd edition. Lippincott Williams & Wilkins; Philadelphia: 2006. p. 449-57
   Google Scholar
• Silberstein SD, Mannix LK, Goldstein J, Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology 2008;71(2):114-21
   PubMed Web of Science ®Google Scholar
• Mannix L, Martin V, Cady R. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Obstet Gynecol 2009;114(1):106-13
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22(8):633-58
   PubMed Web of Science ®Google Scholar
• Mathew NT, Schoenen J, Winner P, Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache 2003;43(3):214-22
   PubMed Web of Science ®Google Scholar
• Fuseau E, Petricoul O, Sabin A, Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine. Clin Ther 2001;23(2):242-51
   PubMed Web of Science ®Google Scholar
• Mandema JW, Cox E, Alderman J. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain–results of a model-based meta-analysis that accounts for encapsulation. Cephalalgia 2005;25(9):715-25
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Teall J, Rodriguez F, Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group. Headache 1998;38(10):748-55
   PubMed Web of Science ®Google Scholar
• Goldstein J, Ryan R, Jiang K, Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group. Headache 1998;38(10):737-47
   PubMed Web of Science ®Google Scholar
• Kolodny A, Polis A, Battisti WP, Rizatriptan Protocol 052 Study Group. Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets. Cephalalgia 2004;24(7):540-6
   PubMed Web of Science ®Google Scholar
• Goadsby P, Ferrari M, Olesen J, Stovner L. Eletriptan in acute migraine. Neurology 2000;54(1):156-63
   PubMed Web of Science ®Google Scholar
• Sandrini G, Färkkilä M, Burgess G, Eletriptan Steering Committee. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Am Acad Neurol 2002;59(8):1210-17
   PubMed Web of Science ®Google Scholar
• Pitman V, Forster E, Jackson N. Comparison of the efficacy of oral eletriptan and oral sumatriptan for the acute treatment of migraine: combined analysis across three clinical trials. Headache 1999;39:374
   Google Scholar
• Spierings EL, Gomez-Mancilla B, Grosz DE, Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol 2001;58(6):944-50
   PubMed Web of Science ®Google Scholar
• Touchon J, Bertin L, Pilgrim A, Ashford E. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 1996;47(2):361-5
   PubMed Web of Science ®Google Scholar
• Diener HC. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. Cephalalgia 1999;19(6):581-8; discussion542
   PubMed Web of Science ®Google Scholar
• Winner P, Ricalde O, Le Force B, Saper J. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996;53(2):180-4
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Henry P, Mulder LJ, The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995;346(8980):923-6
   PubMed Web of Science ®Google Scholar
• The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur. Neurol 1992;32(3):177-84
   PubMed Web of Science ®Google Scholar
• Chabriat H, Joire J, Danchot J, Grippon P. Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double blind placebo controlled study. Cephalalgia 1994;14(4):297-300
   PubMed Web of Science ®Google Scholar
• Diener HC, Bussone G, de Liano H, Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004;24(11):947-54
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. Oral triptans vs. other classes of acute migraine medication. Cephalalgia 2006;26(5):628
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. Unpublished clinical trials with sumatriptan. Lancet 2009;374(9700):1501-2
   PubMed Web of Science ®Google Scholar
• Massiou H. Sumatriptan nasal spray comparator clinical trials. 3rd European Headache Federation Conference. Sardinia; 1996
   Google Scholar
• Graham J, Wolff H. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiatry 1938;39(4):737-63
   Google Scholar
• Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol 1991;31(5):314-22
   PubMed Web of Science ®Google Scholar
• Agency SMP. Monograph on sumatriptan suppositories. Available from: http://www.mpa.se
   Google Scholar
• Tfelt-Hansen P, Saxena P. Ergot alkaloids in the acute treatment of migraine. In: Olesen J, Goadsby P, Ramadan N, Tfelt-Hansen P, Welch K, editors. The headaches. Lippincott Williams & Wilkins; Philadelphia: 2006. p. 459-67
   Google Scholar
• Tfelt-Hansen P, Eickhoff JH, Olesen J. The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients: methodological aspects and time effect curve. Acta Pharmacol Toxicol (Copenh) 1980;47(2):151-6
   PubMedGoogle Scholar
• Tfelt-Hansen P. Over-the-counter triptans for migraine: what are the implications? CNS Drugs 2007;21(11):877-83
   PubMed Web of Science ®Google Scholar
• Minet ML, Massiou H. An instrument to assess patient perceptions of satisfaction with acute migraine treatment (EXPERT Study). Headache 2011;51(4):590-601
   PubMed Web of Science ®Google Scholar
• Welch KM, Mathew NT, Stone P, Tolerability of sumatriptan: clinical trials and post-marketing experience. Cephalalgia 2000;20(8):687-95
   PubMed Web of Science ®Google Scholar
• Lampl C, Voelker M, Diener HC. Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol 2007;254(6):705-12
   PubMed Web of Science ®Google Scholar
• Dahlöf C, Hogenhuis L, Olesen J. Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. Eur J Neurol 1998;5(5):469-77
   PubMed Web of Science ®Google Scholar
• Sargent J, Kirchner JR, Davis R, Kirkhart B. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology 1995;45(8 Suppl 7):S10-14
   PubMed Web of Science ®Google Scholar
• Lipton RB, Dodick DW, Adelman JU, Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled, crossover study. Cephalalgia 2009;29(8):826-36
   PubMed Web of Science ®Google Scholar
• Nett R, Landy S, Shackelford S, Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol 2003;102(4):835-42
   PubMed Web of Science ®Google Scholar
• Landy S, Savani N, Shackelford S. Efficacy and tolerability of sumatriptan tablets administered during the mild‐pain phase of menstrually associated migraine. Int J Clin Pract 2004;58(10):913-9
   PubMed Web of Science ®Google Scholar
• Jelinski SE, Becker WJ, Christie SN, Pain free efficacy of sumatriptan in the early treatment of migraine. Can J Neurol Sci 2006;33(1):73-9
   PubMed Web of Science ®Google Scholar
• Geraud G, Olesen J, Pfaffenrath V, Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia 2000;20(1):30-8
   PubMed Web of Science ®Google Scholar
• Visser WH, Terwindt GM, Reines SA, Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group. Arch Neurol 1996;53(11):1132-7
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia 2002;22(6):453-61
   PubMed Web of Science ®Google Scholar